A Phase 1/2 interventional study of ADX-038 and Placebo in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by ADARx Pharmaceuticals, Inc.. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by ADARx Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia — 2 open to participants now, 3 under way, none of them phase 3. Hemoglobinuria, Paroxysmal · Australia.
Among the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 1/2, and was the 14th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →2 of the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia are open now. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in Australia, United States, France and 4 more countries
Women only
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 7
First in 2004; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 50 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 80 across the 12 interventional studies, 75 across the 3 observational. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 7 most frequent:
ADARx Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 7 are open to participants now.
ADARx Pharmaceuticals, Inc. has 1 study filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).
The clinical study described in this protocol is a Phase 1/Phase 2a study evaluating safety, tolerability, PK, and PD of ADX-038.
The study consists of 2 parts:
Phase 1 Key Inclusion Criteria
Phase 1 Key Exclusion Criteria
Phase 2a Key Inclusion Criteria
Phase 2a Key Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For each cohort in Phase 1 (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
Drug: ADX-038
For each cohort in Phase 1 (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-038): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
Drug: Placebo
This will be initiated at the dose level determined by the Safety Review Committee from SAD in HPs. The treatment of PNH participants is an open-label study.
Drug: ADX-038
siRNA duplex oligonucleotide
Also known as: siRNA
Saline
Also known as: Saline
Safety in Healthy Volunteers
To evaluate the safety and tolerability of ADX-038 in HVs by incidence, relationship, and severity of adverse events and serious adverse events
Time frame: 365 days
Safety in Paroxysmal Nocturnal Hemoglobinuria Participants
Evaluate the safety and tolerability of ADX-038 by incidence, relationship, and treatment-emergent adverse events and serious adverse events.
Time frame: 365 days
Pharmacokinetics in Healthy Participants
To characterize the Pharmacokinetics of ADX-038 in HPs by measuring the Maximum observed plasma concentration (Cmax)
Time frame: 8 days
Pharmacodynamics in Healthy Participants
Change from base in plasma concentrations over time in Complement factor B (CFB) protein via assay measurement
Time frame: 365 days
Pharmacodynamics in Paraxysmal Nocturnal Hemoglobinuria
Evaluate the changes in hemoglobin concentrations
Time frame: 365 days
Pharmacodynamics in Paraxysmal Nocturnal Hemoglobinuria
Characterize the changes in serum concentration of complement factor B (CFB) protein and complement alternative pathway activity level.
Time frame: 365 days
Pharmacodynamics in Healthy Participants
Change in complement alternative pathway activity via assay measurement
Time frame: 365 days
Immune Response in Healthy Participants
Anti-polyethylene glycol (PEG) antibody titers and anti-drug antibody titers
Time frame: 365 days
Pharmacodynamics in Healthy Participants
Change in complement classical pathway activity via assay measurement
Time frame: 365 days
Safety in Paroxysmal Nocturnal Hemoglobinuria Participants
Evaluate the change from baseline in follow up visits for safety assesments
Time frame: 365 days
Clinical Effect in Paroxysmal Nocturnal Hemoglobinuria Participants
Look at time (number of days) from dosing (Day 1) to diminished therapeutics effect (DTE)
Time frame: 365 days
Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
Evaluate changes in lactate dehydrogenase (LDH) (U/L)
Time frame: 365 days
Effects on Hemolysis in Paroxysmal Nocturnal Hemoglobinuria Participants
Evaluate incidence of clinical breakthrough hemolysis, blood transfusions and Incidence of major adverse vascular events (MAVEs)
Time frame: 365 days
Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria
Characterize PK parameters of ADX-038 by plasma C(max)
Time frame: 8 days
Pharmacodynamics in Paraxysmal Nocturnal Hemoglobinuria
Characterize changes in complement classical pathway activity level
Time frame: 365 days
Immune Response in Paraxysmal Nocturnal Hemoglobinuria
Determine Anti-PEG and anti-drug antibody titers
Time frame: 365 days
Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
Evaluate changes in serum free hemoglobin
Time frame: 365 days
Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
Evaluate changes in Haptoglobin Concentrations
Time frame: 365 days
Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
Evaluate changes in Reticulocyte Counts (%)
Time frame: 365 days
Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
Evaluate changes in Bilirubin (umol/L)
Time frame: 365 days
Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
Evaluate changes in Aspartate aminotransferase (U/L)
Time frame: 365 days
Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria
Characterize PK parameters of ADX-038 by plasma AUC (0-infinity)
Time frame: 8 days
Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria
Characterize PK parameters of ADX-038 by plasma AUC(0-last)
Time frame: 8 days
Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria
Characterize PK parameters of ADX-038 by plasma T(max)
Time frame: 8 days
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Mar 2028, 55 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ADX-038
ADARx Pharmaceuticals, Inc.